Inactive Instrument

PRA Health Sciences, Inc.

PRAH

US69354M1080

Biotechnology & Medical Research

PRA Health Sciences, Inc.'s Equity Buyback announced on August 30, 2019, has expired.

July 30, 2021

The company expired its plan on July 1, 2021, on account of its acquisition by ICON Public Limited Company (NasdaqGS:ICLR).

Latest news about PRA Health Sciences, Inc.

Market Chatter: Helixmith Chooses PRA Health Sciences for Phase Three Trials of Engensis	21-08-02	MT
ICON Public : Posts Higher Q2 Results from Year Ago, Updates Guidance -- Stock Down 3% After-Hours	21-07-21	MT
PRA HEALTH SCIENCES : Mizuho Securities Starts PRA Health Sciences at Neutral with $169 Price Target	21-07-06	MT
PRA Health Sciences, Inc.(NasdaqGS:PRAH) dropped from S&P Global BMI Index	21-07-02	CI
PRA Health Sciences, Inc.(NasdaqGS:PRAH) dropped from S&P TMI Index	21-07-02	CI
PRA Health Sciences, Inc.(NasdaqGS:PRAH) dropped from S&P 1000	21-07-02	CI
PRA Health Sciences, Inc.(NasdaqGS:PRAH) dropped from S&P 400 Health Care	21-07-02	CI
PRA Health Sciences, Inc.(NasdaqGS:PRAH) dropped from S&P 400	21-07-02	CI
PRA Health Sciences, Inc.(NasdaqGS:PRAH) dropped from S&P Composite 1500	21-07-02	CI
PRA Health Sciences, Inc. Announces Board Changes	21-07-01	CI
PRA Health Sciences, Inc.(NasdaqGS:PRAH) dropped from NASDAQ Composite Index	21-07-01	CI
PRA Health Sciences, Inc.'s Equity Buyback announced on August 30, 2019, has expired.	21-06-30	CI
ICON Public Limited Company completed the acquisition of PRA Health Sciences, Inc..	21-06-30	CI
PRA Health Sciences, Inc.(NasdaqGS:PRAH) dropped from NASDAQ Biotechnology Index	21-06-30	CI
Allscripts Healthcare : PRA Health Sciences, Allscripts' Veradigm Plan Clinical Research Network Based on Electronic Health Records	21-06-23	MT
Veradigm and PRA Health Sciences Partner to Create the Industry’s Leading EHR-Based Clinical Research Network	21-06-23	CI
ICON Public : Prices $500 Million of Senior Secured Notes	21-06-17	MT
ICON Public : Unit to Raise $2 Billion via Senior Secured Notes Offering	21-06-14	MT
ANALYST RECOMMENDATIONS : Amgen, Biogen, Halfords, J Sainsbury, Uber...	21-06-08
CORRECTION : Mizuho Securities Maintains Price Target for PRA Health Sciences at $169, Reiterates Neutral Rating	21-06-07	MT
PRA HEALTH SCIENCES : Mizuho Securities Adjusts PRA Health Sciences PT to $155 From $169, Maintains Neutral Rating	21-06-07	MT
Pra Health Sciences, Inc. Pioneers Connecting Clinical Trial Patients with Their Real-World Data with Synoma	21-05-13	CI
MOVES-Deutsche Bank hires investment banking veteran Priyanka Verma in healthcare push	21-05-13	RE
PRA HEALTH SCIENCES : Truist Securities Downgrades PRA Health Sciences to Hold From Buy; Price Target is $175	21-05-10	MT
PRA HEALTH SCIENCES : UBS Adjusts Price Target on PRA Health Sciences to $170 From $155 on ICON Deal; Neutral Rating Kept	21-05-03	MT

Chart PRA Health Sciences, Inc.

Duration

Period

More charts

PRA Health Sciences, Inc. is a United States-based company. The Company is a contract research organization. It is engaged in providing outsourced clinical development and data solution services to the biotechnology and pharmaceutical industries. The Company focused on oncology, immunology, central nervous system, inflammation, respiratory, cardiometabolic, and infectious diseases. It operates through two segments: Clinical Research and Data Solutions. The Clinical Research segment provides services across the spectrum of clinical development programs. The Data Solutions segment provides data, analytics, technology and consulting solutions to the life sciences market. The Company offer clinical development service offerings, which include functional outsourcing services, traditional and project based clinical trial services.

Sector

Biotechnology & Medical Research

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
IQVIA HOLDINGS INC.	+2.35%	42.11B
LONZA GROUP AG	+48.94%	40.08B
MODERNA, INC.	+7.46%	40B
CELLTRION, INC.	-11.32%	26.87B
ICON PUBLIC LIMITED COMPANY	+6.20%	24.58B
ALNYLAM PHARMACEUTICALS, INC.	-22.44%	18.44B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	+1.17%	11.94B
MEDPACE HOLDINGS, INC.	+19.07%	11.66B
UNITED THERAPEUTICS CORPORATION	+8.04%	11.01B

Other Biotechnology & Medical Research